Brought to you by:
SVS makes fresh call for active participation in compensation survey
The Society for Vascular Surgery (SVS) has made a fresh call for members to participate in a compensation survey, a collaboration with Phairify, that aims to provide vascular surgeons with tailored insights into compensation, practice and productivity data relevant to…
Changing course: The natural history of tibial claudication comes under scrutiny as interventions for ‘relatively benign’ disease trend upward
In the end, reflected Michael S. Conte, MD, “it’s not the evidence.” The leading vascular surgeon and peripheral arterial disease (PAD) expert made the bold statement during the recent 2023 VEITHsymposium (Nov. 14–18) as he pointedly asked a room full…
Enrollment complete in APEX-AV study of mechanical aspiration system for acute PE
Patient enrollment is now complete in the APEX-AV trial evaluating the safety and efficacy of the AlphaVac F1885 (AngioDynamics) multipurpose mechanical aspiration system for the treatment of acute intermediate-risk pulmonary embolism (PE). APEX-AV is a single-arm investigational device exemption (IDE)…
The top 10 most popular Vascular Specialist stories of November 2023
In November, the most read stories from Vascular Specialist include a reassessment of which carotid revascularization treatment modality is best after the recent Centers for Medicare & Medicaid Services (CMS) coverage expansion; updated analyses from the VOYAGER PAD clinical trial;…
Intravenous anesthesia delivery during varicose vein treatment proves safe and reduces pain scores, researcher reports
A new intravenous anesthesia delivery technique used during endothermal ablation for varicose veins demonstrated comparatively low pain scores according to first-in-human (FIH) data recently presented at the 2023 VEITHsymposium. The investigational Solutio catheter (MedVasc), which contains both a bent needle…
VOYAGER PAD analyses shed light on use of rivaroxaban in high-risk patient populations
New analyses from the VOYAGER PAD clinical trial in both high-risk and fragile patients and those with and without comorbid coronary artery diseases (CAD) were presented at the American Heart Association (AHA) 2023 Scientific Sessions (Nov. 11–13) in Philadelphia. The…
TRANSCEND 36-month data “continue to demonstrate safe and effective performance” of SurVeil DCB
Peter Schneider (University of California San Francisco, San Francisco, USA) recently presented 36-month data from Surmodics’ TRANSCEND clinical trial at the VEITHsymposium 2023 (14–18 November, New York, USA). The TRANSCEND trial is a prospective, multicentre, single-blind randomised controlled trial to…
VAM abstract submissions window opens
VAM program chair Andres Schanzer, MD, makes a call for cutting-edge new science for next year’s meeting in Chicago. Researchers who want to present new science at the 2024 Vascular Annual Meeting (VAM) are encouraged to prepare their abstracts for…
Change: A driving force behind SVS advocacy initiatives
Change is a constant in life, and advocacy is no exception. The healthcare landscape is always evolving, and the SVS Advocacy Council is working to maintain a voice in the decision-making process. The council is committed to driving change that…
The pulmonary arterial tree—it is time we branch out
Nicolas Mouawad, MD, chief of vascular surgery at McLaren Health System in Bay City, Michigan, urges vascular surgeons to “get out of their comfort zone” and become more involved in pulmonary embolism (PE) care. With more than 1 million cases…